1126 IDENTIFICATION OF p90RSK AS A NOVEL THERAPEUTIC TARGET FOR LIVER FIBROSIS
2013; Elsevier BV; Volume: 58; Linguagem: Inglês
10.1016/s0168-8278(13)61127-7
ISSN1600-0641
AutoresOriol Morales‐Ibanez, Silvia Affò, Cristina Millán, Mar Coll, Vicente Arroyo, Pere Ginés, Joan Caballería, Pau Sancho‐Bru, Ramón Bataller,
Tópico(s)Pancreatitis Pathology and Treatment
Resumoable to repress AKT phosphorylation after GAS6 exposure (30 min, 200ng/ml), and overnight treatment of LX2 cells was able to dosedependently decrease basal AKT levels and inhibit GAS6-dependent AKT activation. Conclusions: Our results point to Axl/AKT axis as a relevant mechanism in HSC activation and suggest that Axl targeting may be an interesting therapeutic strategy to reduce liver fibrosis.
Referência(s)